ArticleBMJ open gastroenterology2019

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation.

Christoph Lohan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.